Go Back

Aurobindo Pharma gets USFDA nod for Meropenem injection

IBEF:  March 28, 2017

Aurobindo Pharma has obtained the approval of the US Food & Drug Administration (USFDA) to manufacture and market its product, Meropenem injection 500 mg/vial and 1g/ vial. It is used for treatment of complicated skin and related infections, complicated intra-abdominal infections and bacterial meningitis. The injection is a generic version of Merrem injection, which is manufactured by AstraZeneca Pharmaceuticals. The estimated market size for the product stood at US$ 118 million for the 12-month ending January 2017, as per IMS.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.